aripiprazole has been researched along with methylphenidate in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (28.00) | 29.6817 |
| 2010's | 16 (64.00) | 24.3611 |
| 2020's | 2 (8.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Aubry, JM; Bertschy, G; Bryois, C; Eliez, S; Etter, M; Nanzer, N | 1 |
| Föhr, J; Haukka, J; Kuikanmäki, O; Kuoppasalmi, K; Meririnne, E; Sokero, P; Tiihonen, J; Tuomola, P; Vorma, H | 1 |
| Brennum, LT; Fink-Jensen, A; Hee Bengtsen, C; Petersen, JH; Sager, TN; Sørensen, G; Thomsen, M; Thøgersen, P; Woldbye, DP; Wörtwein, G | 1 |
| Findling, RL | 1 |
| Elkashef, A; Hanson, G; Tiihonen, J; Vocci, F; White, J; Wickes, W | 1 |
| Ketzer, CR; Pheula, GF; Rohde, LA; Tramontina, S; Zeni, CP | 1 |
| Barnett, RJ; Cauble, S; McLaren, JL | 1 |
| Appel, DI; Markowitz, JS; Peterson, YK; Wang, Z; Zhu, HJ | 1 |
| Ekinci, O; Sabuncuoglu, O | 1 |
| Cavanna, AE; Rickards, H; Worrall, R | 1 |
| Chadman, KK; Guariglia, SR; Yoo, JH | 1 |
| Chen, TY; Tzeng, NS | 1 |
| Alparslan, S; Eryilmaz, G; Isiten, N; Mutlu, C; Ozilhan, S; Saglam, E; Yorbik, O | 1 |
| Duncan-Wiebe, G; LeRiger, M; Shukry, M; Williams, J | 1 |
| Naguy, A | 1 |
| Abdelhakim, W; Al-Tajali, A; Naguy, A | 1 |
| Anagnostou, E | 1 |
| Akça, ÖF; Sertdemir, M | 1 |
| Fu, AT; Pan, PY; Yeh, CB | 1 |
| Effatpanah, M; Khoramizadeh, M; Mahjoub, A; Mostaghimi, A; Rezaei, M; Shishehgar, S | 1 |
| Cheng, X; Li, J; Yang, C; Yu, D; Zhang, L; Zhang, Q | 1 |
| Naguy, A; Naguy, C | 1 |
8 review(s) available for aripiprazole and methylphenidate
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Psychiatry].
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Attention Deficit Disorder with Hyperactivity; Humans; Lamotrigine; Mental Disorders; Methylphenidate; Piperazines; Quinolones; Risperidone; Triazines | 2005 |
Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Benzodiazepines; Child; Dibenzothiazepines; Disorders of Excessive Somnolence; Headache; Humans; Methylphenidate; Obesity; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone | 2008 |
Pharmacotherapy of methamphetamine addiction: an update.
Topics: Antipsychotic Agents; Aripiprazole; Bupropion; Central Nervous System Stimulants; Dextroamphetamine; Drug Therapy; Humans; Lobeline; Methamphetamine; Methylphenidate; Narcotic Antagonists; Nicotinic Agonists; Piperazines; Prevalence; Quinolones; Recurrence; Substance-Related Disorders | 2008 |
New directions in the treatment of autism spectrum disorders from animal model research.
Topics: Adolescent; Adolescent Behavior; Animals; Antipsychotic Agents; Aripiprazole; Brain; Central Nervous System Stimulants; Child; Child Behavior; Child Development Disorders, Pervasive; Child, Preschool; Disease Models, Animal; Dopamine Antagonists; Dopamine Uptake Inhibitors; Drug Discovery; GluK2 Kainate Receptor; Glutamic Acid; Humans; Methylphenidate; Mice; Mice, Inbred C57BL; Oxytocin; Piperazines; Quinolones; Rats; Receptors, Kainic Acid; Risperidone; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists | 2012 |
Clinical trials in autism spectrum disorder: evidence, challenges and future directions.
Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Aggression; Antipsychotic Agents; Aripiprazole; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Central Nervous System Depressants; Central Nervous System Stimulants; Clinical Trials as Topic; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Irritable Mood; Melatonin; Metformin; Methylphenidate; Obesity; Outcome Assessment, Health Care; Precision Medicine; Risperidone; Sleep; Sleep Wake Disorders | 2018 |
Treatment of amphetamine abuse/use disorder: a systematic review of a recent health concern.
Topics: Amphetamine-Related Disorders; Aripiprazole; Clinical Trials as Topic; Cognitive Behavioral Therapy; Combined Modality Therapy; Humans; Iran; Methylphenidate; Risperidone | 2019 |
Interventions for tic disorders: An updated overview of systematic reviews and meta analyses.
Topics: Antipsychotic Agents; Aripiprazole; Child; Cost-Benefit Analysis; Exercise; Guanfacine; Humans; Meta-Analysis as Topic; Methylphenidate; Systematic Reviews as Topic; Tic Disorders; Treatment Outcome | 2020 |
3 trial(s) available for aripiprazole and methylphenidate
| Article | Year |
|---|---|
A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence.
Topics: Adult; Amphetamine; Amphetamine-Related Disorders; Aripiprazole; Female; Humans; Male; Methylphenidate; Piperazines; Placebos; Quinolones; Severity of Illness Index; Substance Abuse Detection; Substance Abuse, Intravenous; Treatment Outcome | 2007 |
Methylphenidate combined with aripiprazole in children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder: a randomized crossover trial.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Central Nervous System Stimulants; Child; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Methylphenidate; Piperazines; Psychiatric Status Rating Scales; Quinolones; Severity of Illness Index | 2009 |
Aripiprazole/Methylphenidate Combination in Children and Adolescents with Disruptive Mood Dysregulation Disorder and Attention-Deficit/Hyperactivity Disorder: An Open-Label Study.
Topics: Adolescent; Antidepressive Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Comorbidity; Drug Therapy, Combination; Female; Humans; Male; Methylphenidate; Neuropsychological Tests | 2018 |
14 other study(ies) available for aripiprazole and methylphenidate
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Aripiprazole blocks acute self-administration of cocaine and is not self-administered in mice.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Brain; Central Nervous System Stimulants; Cocaine; Cocaine-Related Disorders; Dose-Response Relationship, Drug; Male; Methylphenidate; Mice; Mice, Inbred Strains; Motivation; Motor Activity; Motor Skills; Piperazines; Quinolones; Radioligand Assay; Receptors, Dopamine D2; Self Administration | 2008 |
Aripiprazole induced acute dystonia after discontinuation of a stimulant medication.
Topics: Acute Disease; Antipsychotic Agents; Aripiprazole; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Central Nervous System Stimulants; Child; Drug Administration Schedule; Dystonia; Humans; Male; Methylphenidate; Piperazines; Quinolones; Substance Withdrawal Syndrome | 2010 |
Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: potential sources of metabolic drug interactions.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Attention Deficit Disorder with Hyperactivity; Carboxylic Ester Hydrolases; Central Nervous System Stimulants; Cluster Analysis; Drug Evaluation, Preclinical; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Humans; Hydrolysis; Inactivation, Metabolic; Male; Methylphenidate; Mice; Models, Molecular; Piperazines; Quinolones | 2010 |
Psychosis associated with switching from risperidone to aripiprazole in an adolescent on methylphenidate treatment.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Central Nervous System Stimulants; Humans; Male; Methylphenidate; Piperazines; Psychoses, Substance-Induced; Quinolones; Risperidone | 2011 |
Treatment practices in Tourette syndrome: the European perspective.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Anxiety; Aripiprazole; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Clonidine; Depression; Europe; Fluoxetine; Fluvoxamine; Health Care Surveys; Humans; Methylphenidate; Obsessive-Compulsive Disorder; Physicians; Piperazines; Propylamines; Psychiatry; Quinolones; Risperidone; Sertraline; Sulpiride; Tourette Syndrome | 2012 |
Aripiprazole: a dopamine modulator that mimics methylphenidate in producing faster antidepressant effects.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Dopamine Agents; Humans; Methylphenidate; Models, Theoretical; Piperazines; Quinolones | 2013 |
Plasma Methylphenidate Levels in Youths With Attention Deficit Hyperactivity Disorder Treated With OROS Formulation.
Topics: Administration, Oral; Adolescent; Aripiprazole; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Interactions; Female; Fluoxetine; Humans; Male; Methylphenidate; Retrospective Studies; Risperidone; Sertraline | 2015 |
Acute masseter dystonia in a pediatric patient receiving aripiprazole and methylphenidate following induction of general anesthesia.
Topics: Anesthesia, General; Antipsychotic Agents; Appendectomy; Aripiprazole; Central Nervous System Stimulants; Child; Clonidine; Diphenhydramine; Dystonia; Histamine H1 Antagonists; Humans; Male; Methylphenidate; Trismus | 2017 |
Pharmacotherapy of Attention Deficit Hyperactivity Disorder Symptom Profile in ASD.
Topics: Aripiprazole; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Clonidine; Comorbidity; Cross-Sectional Studies; Guanfacine; Humans; Methylphenidate; Randomized Controlled Trials as Topic; Risperidone; Social Adjustment; Treatment Outcome | 2017 |
Two Adolescent Cases of Psychotropic-Related Nonaffective Oniomania.
Topics: Adolescent; Aripiprazole; Disruptive, Impulse Control, and Conduct Disorders; Female; Humans; Methylphenidate; Psychotropic Drugs | 2018 |
Aripiprazole Treatment of Compulsive Behaviors Associated With Methylphenidate in a Child With Down Syndrome.
Topics: Antipsychotic Agents; Aripiprazole; Child; Compulsive Behavior; Dopamine Uptake Inhibitors; Down Syndrome; Female; Humans; Methylphenidate | 2018 |
Trichotieromania and Alopecia Areata Triggered by Aripiprazole-Methylphenidate Combo in an Autistic Child: The Nexus of Impulsivity-Compulsivity.
Topics: Alopecia Areata; Aripiprazole; Autistic Disorder; Child; Humans; Impulsive Behavior; Methylphenidate | 2022 |